SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs sharp rally is drawing attention to Starknets quantum-resistant STARK technology and speculation about a possible transition from an Ethereum L2 to an independent L1. Traders are largely bullish and chasing momentum, while others warn the move could fade and point to profit-taking.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

A reported Hyperbridge exploit involving an Ethereum-based wrapped DOT token is fueling security concerns, though some traders emphasize that native Polkadot DOT was not affected. The discussion also reflects sharp disagreement over DOTs weak price performance and whether recent rebounds can hold.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

AEROs sharp move has traders focused on a test of the psychological $1 level, with bullish posts anticipating a breakout and others warning of resistance or a pullback. Optimism is also tied to the planned AerodromeVelodrome merger and broader multichain expansion, though the rollouts effect on the token remains uncertain.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes BLA submission for sonelokimab in hidradenitis suppurativa and the pending FDA review decision are driving discussion, with traders debating the potential for priority review against regulatory risk. The community is also weighing the muted share-price response and managements go-it-alone commercialization strategy against hopes for a partnership or buyout.

Neon EVM is the EVM on Solana (currently on devnet), which enables Ethereum-based applications to have access to Solana’s scalability and liquidity without any changes to their codebase. Neon EVM is a smart contract on Solana. Solana is a fast-growing blockchain, Neon EVMs performance has been tested through multiple use cases, and the platform now includes the infrastructure and capabilities to support production level development. Notable Ethereum-based projects starting to build on Neon include Curve and Sobal (Balancer friendly fork). Neon EVM has over 200 projects in its pipeline committed to launching shortly after the launch of mainnet, including blue-chip DeFi protocols, wallets, bridges, fiat on/off ramps, infrastructure, DAO tooling, etc. The focus in the early stages will be providing the infrastructure and technical dependencies needed for a breadth of use cases to expand from EVM chains to Solana. Looking beyond mainnet, the plan is to develop interoperability with Solana smart contracts, full ecosystem compatibility, integration with additional major Ethereum tools and services, EVM support for Saga and an early grants program. Deploying on Neon EVM will onboard new users &amp; increase user activity on Aave by decreasing costs compared to Ethereum and enabling users to take advantage of Solana liquidity and access to the overall ecosystem Neon EVM is an Ethereum Virtual Machine (EVM) built into a Solana smart contract, enabling Ethereum developers to build on Solana and access its native ecosystem without changing their codebases. Neon EVM facilitates the usage of Ethereum tooling by dApp developers to scale and access unaddressed liquidity on Solana. Developers can utilize the vast majority of Ethereum dev tools

Neon EVM

NEONs volatile swings and persistent selling are driving discussion, with traders split between calling a bottom and expecting further declines. Some attribute the sharp moves to thin liquidity and raise concerns about token unlocks and circulating supply, while others see the selloff as a buying opportunity.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visas rally toward fresh highs and bullish technical momentum are drawing attention, with traders citing breakout patterns and strong price action. Sentiment is mostly positive, though some see the stock as overextended and expect profit-taking or a pullback.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Traders are focused on reports of FDA review documents showing a weaker response rate for daraxonrasib in KRAS G12D pancreatic cancer than in other mutation subgroups, raising questions about the drugs efficacy across patients and opening a competitive debate with Verastems G12D program. Some investors view the subgroup response data as concerning, while others argue that overall survival and progression-free-survival results matter more and caution that subgroup comparisons may not be definitive.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastems planned VS-7375 clinical update across pancreatic, lung and colorectal cancers is the main focus, with traders comparing encouraging GenFleet results and recent questions about competing KRAS drugs against the need for Verastems own data to confirm efficacy, durability and tolerability. Sentiment is hopeful but cautious, and some investors are frustrated that pipeline developments have not lifted the share price more; RAMP 201 ovarian-cancer analyses are a secondary topic.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

A broad rally in Brazilian equities following Flvio Bolsonaros stronger-than-expected first-round showing is driving attention to Petrobras, as traders speculate that a more shareholder-friendly political outlook could support a re-rating. Others caution that the runoff is unresolved and debate taking profits after the stocks breakout.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol Myers is drawing attention over mixed pipeline developments: positive Phase 3 multiple-myeloma data and an expanded Camzyos indication are being weighed against a Leerink downgrade citing uncertainty around upcoming readouts and commercial prospects. Traders are debating whether the positive clinical progress can offset pipeline and execution concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
